GTBP
GT Biopharma, Inc.
Next earnings Aug 12, 2026 · consensus $-0.08 EPS
Last earnings +26.2% on 2025-11-14
$0.43
▲ 0.00%$0.43▼ -86.60%
over 1Y
L $0.27EODHDH $3.80
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.0%
1W-12.4%
1M+8.9%
3M+5.1%
YTD-47.4%
1Y-86.6%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
High return on equity (109.6%).
Revenue (FY2020) $0.00 · FY2020
GT Biopharma, Inc. shows $0.00 in FY2020 revenue, and 109.6% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$57.5M | -$21.3M | -$13.6M | -$14.4M | -$12.4M |
| Net income | -$58.0M | -$20.9M | -$7.60M | -$13.2M | -$28.4M |
| Diluted EPS | — | -$19.66 | -$5.64 | -$6.94 | -$6.68 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$6.76M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-209.0%
FCF yield-95.2%
Quality & risk
ROIC (est.)—
Free cash flow-$12.9M
Total debt—
Net cash$6.81M
Altman Z-Score-147.24 distress
Piotroski F-Score2/7
Capital returns
Buyback yield—
Dividend yield (est.)1.7%
Shareholder yield1.7%
Shares Δ YoY+1312.2%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — delisting notice (2026-05-22). Worth a closer look.
- 8-K Charter / bylaws change2026-06-12
- 8-K Delisting notice2026-05-22
- 10-Q Quarterly report2026-05-15
- S-1 Securities registration2026-04-30
- 8-K Material agreement2026-04-07
- 10-Q/A Restated periodic report2026-03-06
- 10-Q/A Restated periodic report2026-03-06
- 8-K Restatement (non-reliance)2026-03-02
- 10-K Annual report2026-03-02
Recent filings
all on EDGAR ↗PRE 14APeriod ending 2026-06-182026-06-18open ↗8-KPeriod ending 2026-06-082026-06-12open ↗8-KPeriod ending 2026-05-202026-05-22open ↗10-QPeriod ending 2026-03-312026-05-15open ↗EFFECTFiling2026-05-13open ↗424B3Filing2026-05-13open ↗S-1Filing2026-04-30open ↗8-KPeriod ending 2026-04-032026-04-07open ↗10-Q/APeriod ending 2025-06-302026-03-06open ↗10-Q/APeriod ending 2025-09-302026-03-06open ↗10-KPeriod ending 2025-12-312026-03-02open ↗8-KPeriod ending 2026-03-012026-03-02open ↗
Frequently asked
- Is GT Biopharma, Inc. (GTBP) a buy?
- GTBP currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. High return on equity (109.6%).
- What is GT Biopharma, Inc.'s quality score?
- GTBP scores 18.999999999999996/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000109657, latest 10-Q filed 2026-05-15) · EODHD · as of 6/21/2026, 4:18:52 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.